New hope for rare bleeding disorder: experimental drug JCXH-213 enters human trials

This early-stage study tests a new drug called JCXH-213 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes only 4 people whose ITP did not improve with standard treatments. The main goal is to check safety and find the right dose, while also seeing if it can raise platelet counts.